Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

NCT07162818 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment

Interventions

DRUG: Nepafenac 0.1% eyedrops
DRUG: Control (placebo) group

Sponsor

Indonesia University